Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

Jan 27 (Reuters) - ‌The ​U.S. ‌Centers for ​Medicare & Medicaid ‍Services on ​Tuesday ​named a ⁠new group of branded drugs ...

U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss ...

Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major ...

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Public Citizen filed a lawsuit against the Trump administration in the U.S. District Court for the District of Columbia ...

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 pandemic.

In his push to “lower prescription drug prices for all Americans,” President Donald Trump is calling on three specific ...